Compare · HKPD vs MCK
HKPD vs MCK
Side-by-side comparison of Cellyan Biotechnology Co. Ltd (HKPD) and McKesson Corporation (MCK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both HKPD and MCK operate in Other Pharmaceuticals (Health Care), so they compete in similar markets.
- MCK is the larger of the two at $101.43B, about 6699.2x HKPD ($15.1M).
- Over the past year, HKPD is down 28.6% and MCK is up 18.5% - MCK leads by 47.1 points.
- MCK has been more active in the news (4 items in the past 4 weeks vs 1 for HKPD).
- MCK has more recent analyst coverage (25 ratings vs 0 for HKPD).
- Company
- Cellyan Biotechnology Co. Ltd
- McKesson Corporation
- Price
- $0.65-12.02%
- $828.02-0.90%
- Market cap
- $15.1M
- $101.43B
- 1M return
- +0.03%
- -5.81%
- 1Y return
- -28.57%
- +18.54%
- Industry
- Other Pharmaceuticals
- Other Pharmaceuticals
- Exchange
- NASDAQ
- NYSE
- IPO
- 2025
- News (4w)
- 1
- 4
- Recent ratings
- 0
- 25
McKesson Corporation
McKesson Corporation provides healthcare supply chain management, retail pharmacy, community oncology and specialty care, and healthcare information solutions in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs and other healthcare-related products. This segment also provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies. The International segment offers distribution and services to wholesale, institutional, and retail customers in 13 European countries and Canada. The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers. The RxTS segment offers CoverMyMeds solution to help patients get the medications; RelayHealth, a workflow solution; RxCrossroads solution for therapies and interventions to biopharma manufacturers; and McKesson Prescription Automation, a customized pharmacy automation technology; and Multi-Client Central Fill as a Service, a pharmacy. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.
Latest HKPD
- SEC Form EFFECT filed by Cellyan Biotechnology Co. Ltd
- SEC Form F-1 filed by Cellyan Biotechnology Co. Ltd
- SEC Form 6-K filed by Cellyan Biotechnology Co. Ltd
- SEC Form 6-K filed by Cellyan Biotechnology Co. Ltd
- SEC Form 6-K filed by Cellyan Biotechnology Co. Ltd
- Cellyan Biotechnology Co., Ltd Receives Nasdaq Notice of Bid Price Deficiency
- SEC Form 6-K filed by Hong Kong Pharma Digital Technology Holdings Limited
- SEC Form 6-K filed by Hong Kong Pharma Digital Technology Holdings Limited
- Hong Kong Pharma Digital Announced Results of 2025 Annual Meeting of Stockholders
- SEC Form 6-K filed by Hong Kong Pharma Digital Technology Holdings Limited
Latest MCK
- McKesson Corporation Declares Quarterly Dividend
- McKesson Signs Agreement with Apollo Funds for Strategic Minority Interest in Medical-Surgical Solutions
- SEC Form 3 filed by new insider Fraga Francisco
- McKesson Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
- Amendment: SEC Form SCHEDULE 13G/A filed by McKesson Corporation
- McKesson Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- McKesson Corporation Announces Fourth Quarter Fiscal 2026 Earnings Release Date and Participation in Upcoming Conferences
- McKesson Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- McKesson Announces Planned CFO Transition
- EVP and Chief Legal Officer Lau Michele sold $2,697,750 worth of shares (2,725 units at $990.00), decreasing direct ownership by 46% to 3,247 units (SEC Form 4)